<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1405-9940</journal-id>
<journal-title><![CDATA[Archivos de cardiología de México]]></journal-title>
<abbrev-journal-title><![CDATA[Arch. Cardiol. Méx.]]></abbrev-journal-title>
<issn>1405-9940</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Cardiología Ignacio Chávez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1405-99402018000500391</article-id>
<article-id pub-id-type="doi">10.1016/j.acmx.2017.11.003</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Utility of myeloperoxidase in the differential diagnosis of acute coronary syndrome]]></article-title>
<article-title xml:lang="es"><![CDATA[Utilidad de la determinación de mieloperoxidasa en el diagnóstico diferencial del síndrome coronario agudo]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Calmarza]]></surname>
<given-names><![CDATA[Pilar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lapresta]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lahoz]]></surname>
<given-names><![CDATA[Raquel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Povar]]></surname>
<given-names><![CDATA[Javier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universitary Hospital Miguel Servet Department of Clinical Biochemistry ]]></institution>
<addr-line><![CDATA[ Zaragoza]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Barbastro Hospital Department of Preventive Medicine, ]]></institution>
<addr-line><![CDATA[ Huesca]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,University Hospital Miguel Servet Department of Endocrinology ]]></institution>
<addr-line><![CDATA[ Zaragoza]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,University Hospital Miguel Servet Department of Urgences, ]]></institution>
<addr-line><![CDATA[ Zaragoza]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2018</year>
</pub-date>
<volume>88</volume>
<numero>5</numero>
<fpage>391</fpage>
<lpage>396</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1405-99402018000500391&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1405-99402018000500391&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1405-99402018000500391&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objectives:  To determine the usefulness of myeloperoxidase in discriminating between patients with acute coronary syndrome and patients with chest pain by other causes.  Methods:  The study included all patients over 18 years of age who come consecutively to the emergency department from September 2015 to December 2015 with chest pain of non- traumatic origin. The initial patient evaluation was performed according to the study protocol for patients with suspected acute coronary syndrome (ACS) in our Emergency Department. This included the serial measurement of troponin, and in this case myeloperoxidase, with serialization on admission and at 6 h. For the determination of myeloperoxidase (MPO), a single step sandwich enzyme immunoassay by Siemens, automated on a Dimension analyser, was used.  Results:  Statistically significant differences were observed in the concentration of myeloperoxidase at time 0 among patients diagnosed with ACS: 505 (413) pmol/L, and non-ACS patients: 388 (195) pmol/L (p &lt; .001), as well as at 6 h (p &lt; .001). An area under the curve ROC of 0.824 was obtained at 6 h for ACS patients, with a confidence interval of 95% from 0.715 to 0.933 and a level of significance of p &lt;.001. Statistically significant differences were also found in the concentration of myeloperoxidase at time 0 and at 6 h among patients with ACS and patients with heart disease other than coronary artery disease.  Conclusions:  The concentration of MPO helps to differentiate between ACS and non-ACS patients, as well as between ACS patients and patients with heart diseases other than coronary artery disease.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivos:  Conocer la utilidad de mieloperoxidasa (MPO) para discriminar entre pacientes con síndrome coronario agudo y dolor torácico de otras causas.  Métodos:  De septiembre a diciembre de 2015 se incluyeron todos los pacientes mayores de 18 años que acudieron de forma consecutiva al servicio de urgencias con dolor torácico de origen no traumático. La evaluación inicial del paciente se realizó de acuerdo con el protocolo de estudio para pacientes con sospecha de síndrome coronario agudo (SCA) en nuestro servicio de urgencias, que incluye la medición de troponina y en este caso MPO, con serialización al ingreso y a las 6 h. Para la determinación de MPO se utilizó un inmunoensayo enzimático de tipo sándwich, de una sola etapa de Siemens, automatizado en un equipo Dimension .  Resultados:  Se obtuvieron diferencias estadísticamente significativas en la concentración de MPO a tiempo 0 entre los pacientes con diagnóstico de SCA: 505 (413) pmol/l y los pacientes no SCA: 388 (195 pmol/l (p &lt; 0.001), así como a las 6 h (p &lt; 0.001). Se obtuvo a las 6 h un área bajo la curva ROC para pacientes con SCA de 0.824 con un intervalo de confianza del 95% de 0.715 a 0.933 y un grado de significación p &lt; 0.001. También se obtuvieron diferencias estadísticamente significativas en la concentración de MPO tanto a tiempo 0 como a las 6 h entre pacientes con SCA y pacientes con enfermedad cardiaca diferente de enfermedad coronaria.  Conclusiones:  La concentración de MPO sirve para diferenciar entre pacientes SCA y pacientes que no son SCA, así como entre pacientes SCA y pacientes con otras enfermedades cardiacas diferentes a la enfermedad coronaria.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Myeloperoxidase]]></kwd>
<kwd lng="en"><![CDATA[Acute coronary syndrome]]></kwd>
<kwd lng="en"><![CDATA[Unstable angina]]></kwd>
<kwd lng="en"><![CDATA[Emergency department]]></kwd>
<kwd lng="en"><![CDATA[Chest pain]]></kwd>
<kwd lng="en"><![CDATA[Spain]]></kwd>
<kwd lng="es"><![CDATA[Mieloperoxidasa]]></kwd>
<kwd lng="es"><![CDATA[Síndrome coronario agudo]]></kwd>
<kwd lng="es"><![CDATA[Angina inestable]]></kwd>
<kwd lng="es"><![CDATA[Servicio de urgencias]]></kwd>
<kwd lng="es"><![CDATA[Dolor torácico]]></kwd>
<kwd lng="es"><![CDATA[España]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nicholls]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hazen]]></surname>
<given-names><![CDATA[SL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myeloperoxidase and cardiovascular disease.]]></article-title>
<source><![CDATA[Arterioscler Thromb Vasc Biol]]></source>
<year>2005</year>
<volume>25</volume>
<page-range>1102---11.</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brennan]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Hazen]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment]]></article-title>
<source><![CDATA[Curr Opin Lipidol.]]></source>
<year>2003</year>
<volume>14</volume>
<page-range>353---9.</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buffon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Biasucci]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Liuzzo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Widespread coronary inflammation in unstable angina.]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>2002</year>
<volume>347</volume>
<page-range>5---12.</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jaremo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hansson]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Nilsson]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Elevated inflammatory parameters are associated with lower platelet density in acute myocardial infarctions with ST-elevation.]]></article-title>
<source><![CDATA[Thromb Res.]]></source>
<year>2000</year>
<volume>100</volume>
<page-range>471---8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loria]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Dato]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Graziani]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes.]]></article-title>
<source><![CDATA[Mediators Inflamm.]]></source>
<year>2008</year>
<volume>2008</volume>
<page-range>135625</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zouridakis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Avanzas]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Arroyo-Espliguero]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris.]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2004</year>
<volume>110</volume>
<page-range>1747---53.</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roman]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Camargo]]></surname>
<given-names><![CDATA[PV]]></given-names>
</name>
<name>
<surname><![CDATA[Borges]]></surname>
<given-names><![CDATA[FK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients.]]></article-title>
<source><![CDATA[Coron Artery Dis]]></source>
<year>2010</year>
<volume>21</volume>
<page-range>129---36.</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shih]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Datwyler]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations.]]></article-title>
<source><![CDATA[Clin Chem]]></source>
<year>2008</year>
<volume>54</volume>
<page-range>1076---9.</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Austen]]></surname>
<given-names><![CDATA[WG]]></given-names>
</name>
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Frye]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for grading of coronary artery disease, council on cardiovascular surgery, American Heart Association.]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1975</year>
<volume>51</volume>
<page-range>5---40.</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hamm]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A classification of unstable angina revisited.]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2000</year>
<volume>102</volume>
<page-range>118---22.</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Brennan]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association between myeloperoxidase levels and risk of coronary artery disease.]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2001</year>
<volume>286</volume>
<page-range>2136---42.</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goldmann]]></surname>
<given-names><![CDATA[BU]]></given-names>
</name>
<name>
<surname><![CDATA[Rudolph]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Rudolph]]></surname>
<given-names><![CDATA[TK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neutrophil activation precedes myocardial injury in patients with acute myocardial infarction.]]></article-title>
<source><![CDATA[Free Radic Biol Med.]]></source>
<year>2009</year>
<volume>47</volume>
<page-range>79---83.</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baldus]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Heeschen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Meinertz]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CAPTURE Investigators. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes.]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2003</year>
<volume>108</volume>
<page-range>1440---5</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heslop]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Frohlich]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[JS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography.]]></article-title>
<source><![CDATA[J Am Coll Cardiol.]]></source>
<year>2010</year>
<volume>55</volume>
<page-range>1102---9.</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kutter]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Devaquet]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Vanderstocken]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit?]]></article-title>
<source><![CDATA[Acta Haematol]]></source>
<year>2000</year>
<volume>104</volume>
<page-range>10---5</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nikpoor]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Turecki]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fournier]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians]]></article-title>
<source><![CDATA[Am Heart J.]]></source>
<year>2001</year>
<volume>142</volume>
<page-range>336---9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Asselbergs]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
<name>
<surname><![CDATA[Reynolds]]></surname>
<given-names><![CDATA[WF]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen-Tervaert]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease.]]></article-title>
<source><![CDATA[Am J Med.]]></source>
<year>2004</year>
<volume>116</volume>
<page-range>429---30.</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Samsamshariat]]></surname>
<given-names><![CDATA[SZ]]></given-names>
</name>
<name>
<surname><![CDATA[Basati]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Movahedian]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Elevated plasma myeloperoxidase levels in relation to circulating inflammatory markers in coronary artery disease.]]></article-title>
<source><![CDATA[Biomark Med.]]></source>
<year>2011</year>
<volume>5</volume>
<page-range>377---85</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sugiyama]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Okada]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sukhova]]></surname>
<given-names><![CDATA[GK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Macrophage myeloperoxidase regulation by granulocyte macrophage colonystimulating factor in human atherosclerosis and implications in acute coronary syndromes.]]></article-title>
<source><![CDATA[Am J Pathol]]></source>
<year>2001</year>
<volume>158</volume>
<page-range>879---91</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rudolph]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Steven]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gehling]]></surname>
<given-names><![CDATA[UM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Coronary plaque injury triggers neutrophil activation in patients with coronary artery disease.]]></article-title>
<source><![CDATA[Free Radic Biol Med]]></source>
<year>2007</year>
<volume>42</volume>
<page-range>460---5</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sawicki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sypniewska]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kozinski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic efficacy of myeloperoxidase for the detection of acute coronary syndromes]]></article-title>
<source><![CDATA[Eur J Clin Invest]]></source>
<year>2011</year>
<volume>41</volume>
<page-range>667---71</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eggers]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Dellborg]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Johnston]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myeloperoxidase is not useful for the early assessment of patients with chest pain.]]></article-title>
<source><![CDATA[Clin Biochem.]]></source>
<year>2010</year>
<volume>43</volume>
<page-range>240---5.</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brennan]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Penn]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Van Lente]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic value of myeloperoxidase in patients with chest pain.]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>2003</year>
<volume>349</volume>
<page-range>1595---604.</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mocatta]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pilbrow]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Cameron]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction.]]></article-title>
<source><![CDATA[J Am Coll Cardiol.]]></source>
<year>2007</year>
<volume>49</volume>
<page-range>1993---2000.</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cavusoglu]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ruwende]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Eng]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome.]]></article-title>
<source><![CDATA[Am J Cardiol.]]></source>
<year>2007</year>
<volume>99</volume>
<page-range>1364---8.</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
